小剂量利妥昔单抗在治疗系统性红斑狼疮中的作用分析  

Analysis of the Effect of Small Dose of Rituximab in the Treatment of Systemic Lupus Erythematosus

作　　者：邱敏丽[1] 金欧[1] 方霖楷[1] 古洁若[1] 

机构地区：[1]中山大学附属第三医院风湿免疫科,广东广州510630

出　　处：《中外医疗》2013年第25期21-22,共2页China & Foreign Medical Treatment

摘　　要：目的探讨小剂量利妥昔单抗(RTX)治疗系统性红斑狼疮(SLE)的疗效及安全性,为传统治疗不能耐受和疗效不佳者提供新的治疗途径。方法对该院收治的27例抗对传统方法治疗效果不佳的SLE患者,给予静脉滴注RTX100 mg,使用4次,同时依病情联用糖皮质激素和/或其他细胞毒药物。采用英国狼疮评估小组(BILAG)和SLE疾病活动指数(SLEDAI)积分对病情进行评估,观察疗效和监测不良反应。结果 27例使用RTX的SLE患者,至随访终点临床完全缓解、部分缓解和无效分别占总例数的48.1%,33.3%和18.5%,BILAG和SLEDAI明显改善,差异有统计学意义。研究期间共发生3例感染,其中只有1例为严重感染。结论小剂量利妥昔单抗对传统方法治疗效果不佳的SLE效果显著,安全性较好,但与细胞毒药物联用时需警惕继发严重感染。Objective To study the effects and safety of small dose of rituximab （RTX） on patients with systemic lupus erythemato- sus（SLE） so as to provide a new way of treatment for patients who are intolerant of traditional treatment or have poor efficacy of conventional treatment. Methods 27 SLE patients with poor efficacy of conventional treatment admitted in our hospital were given RTX 100 mg intravenously, 4 times a day. In addition, they were given glucocorticoid or other cytotoxic drugs according to the pa- tient＇s condition. SLE activity was evaluated by the BILAG and the SLEDAI. The efficacy was observed and the side effects were monitored. Results At the end of follow-up, complete remission, partial remission and non-remission rates of the patients was 48.1%, 33.3% and 18.5%, respectively. Significant clinical improvement was noted with BILAG and SLEDAI, the difference was statistically significant. 3 cases of infections were observed, of which, only 1 case with severe infection. Conclusion Small dose of rituximab therapy is safe and has good effects on SLE patients with poor efficacy of conventional treatment, but it is necessary to guard against severe infection while combinating with cytotoxic drugs,

关 键 词：利妥昔单抗 系统性红斑狼疮 治疗效果 不良反应 

分 类 号：R593[医药卫生—内科学]